Buprenorphin/Naloxon "G.L. Pharma" 4+1 mg resoribletter, sublinguale Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphin/naloxon "g.l. pharma" 4+1 mg resoribletter, sublinguale

g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 4+1 mg

Libroxar 2+0,5 mg resoribletter, sublinguale Dinamarca - dinamarquês - Lægemiddelstyrelsen (Danish Medicines Agency)

libroxar 2+0,5 mg resoribletter, sublinguale

laboratoires smb s.a. - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 2+0,5 mg

Vectibix União Europeia - dinamarquês - EMA (European Medicines Agency)

vectibix

amgen europe b.v. - panitumumab - kolorektale neoplasmer - antineoplastiske midler - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. i anden linje i kombination med folfiri for patienter, der har modtaget første linje fluoropyrimidine-baseret kemoterapi (undtagen irinotecan). som monoterapi efter svigt af fluoropyrimidine-, oxaliplatin eller irinotecan-holdig kemoterapi regimer.